In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies

(2016) Luc Dirix et al.   CLINICAL THERAPEUTICS

ERRATUM

(2016)   JOURNAL OF CLINICAL ONCOLOGY

Drug–Drug Interactions Based on Pharmacogenetic Profile between Highly Active Antiretroviral Therapy and Antiblastic Chemotherapy in Cancer Patients with HIV Infection

(2016) Massimiliano Berretta et al.   Frontiers in Pharmacology

Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation

(2015) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular mechanisms of the microsomal mixed function oxidases and biological and pathological implications

(2015) Arthur I. Cederbaum   Redox Biology

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

(2014) Jonathan Ledermann et al.   LANCET ONCOLOGY

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

(2013) Ulrich M. Zanger et al.   PHARMACOLOGY & THERAPEUTICS

Effects of CYP Induction by Rifampicin on Tamoxifen Exposure

(2012) L Binkhorst et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole

(2010) Landry K. Kamdem et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Oxidative stress, inflammation, and cancer: How are they linked?

(2010) Simone Reuter et al.   FREE RADICAL BIOLOGY AND MEDICINE

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and Pharmacokinetics

(2009) ET Morgan   CLINICAL PHARMACOLOGY & THERAPEUTICS

Current Industrial Practices in Assessing CYP450 Enzyme Induction: Preclinical and Clinical

(2008) Michael Sinz et al.   AAPS Journal

Inhibition and induction of human cytochrome P450 enzymes: current status

(2008) Olavi Pelkonen et al.   ARCHIVES OF TOXICOLOGY

Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin

(2008) B. Evers et al.   CLINICAL CANCER RESEARCH

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

(2008) S. Rottenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA